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PREFACE
The 4th scientific meeting entitled “Tumors of the gastrointestinal tract: 
immunotherapy and targeted therapy of colorectal cancer” was organised on 
December 21, 2017 by the Croatian Academy of Sciences and Arts, Department 
of Medical Sciences, and the School of Medicine of the University of Zagreb, 
Department of Clinical Oncology. The Organizing Committee comprised the 
following members - clinical oncologists of the Department of Clinical Onco-
logy: professor Lidija Beketić-Orešković, MD, PhD, professor Ante Bolanča, MD, 
PhD, professor Nikola Đaković, MD, PhD, professor Ana Fröbe, MD, PhD, Marija 
Gamulin, MD, PhD, professor Antonio Juretić, MD, PhD, academician professor 
Zvonko Kusić, MD, PhD, Jasmina Marić Brozić, MD, PhD, Jasna Radić, MD, PhD, 
Zoran Rakušić, MD, PhD, Željko Soldić, MD, and professor Fedor Šantek, MD, 
PhD.
Colorectal cancer (CRC) is one of the most frequent types of cancer as well as 
one of the most frequent causes of death among cancer patients worldwide. Cli-
nical experience supported by various patohistological and molecular biology 
data indicates that CRC is a heterogeneous disease. Active oncological systemic 
treatment of patients having metastatic CRC nowadays includes fluoropyrimi-
dines alone or in combination with irinotecan and/or oxaliplatin ± monoclonal 
antibodies (mAbs) such as bevacizuma, cetuximab, panitumumab, multi-kinase 
inhibitor regorafenib and recombinant fusion protein aflibercept. Recent progre-
ss in colorectal cancer genome analysis, also supported by clinical observations, 
indicates that patients with DNA mismatch repair deficiency or microsatellite 
instability-high metastatic colorectal cancers are a distinct biomarker-defined 
population that might benefit from immunotherapy treatment with monoclonal 
antibodies against checkpoint molecules. These are monoclonal pembrolizu-
mab and nivolumab which are directed against molecule programmed cell de-
ath 1 (PD-1) on T-lymphocytes. The above mentioned treatment possibilities for 
patients having metastatic colorectal cancer have significantly improved their 
median overall survival (OS). These novel approaches to treatment decisions 
should be patient personalized, i.e. such decisions should be tailored according 
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to patient clinical (age, performance status, comorbidities) and molecular (phar-
macogenetic) characteristics, tumor disease stage, tumor location and tumor 
molecular characteristics, and patient preferences. Treatment decisions for pati-
ents with metastatic CRC must be evidence based. The role of the multidiscipli-
nary team in recommendation preparation is unavoidable.
The meeting focused on diagnostic molecular characteristics of colorectal 
cancer (CRC) and treatment options for patients having CRC, more specifically 
targeted therapy and immunotherapy. Since similar symposia had already been 
organized in the previous years, the aim of this meeting was to summarize the 
findings made public in the period between the previous and this symposium.
The topics presented included CRC molecular subtypes, patohistological 
prognostic and predictive parameters, recommendations and algorithms, an 
overview of surgical approaches taking into account tumor sidedness, CRC 
immunotherapy approaches and a brief overview of nutritive support re-
commendations and preparations available to CRC patients. We hope that the 
papers presented will provide readers with sufficient information enabling 
them to better understand the recent findings on colorectal cancer pathogenesis, 
diagnosis and treatment options in the clinical setting.
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